gingerol and Pseudomonas-Infections

gingerol has been researched along with Pseudomonas-Infections* in 4 studies

Other Studies

4 other study(ies) available for gingerol and Pseudomonas-Infections

ArticleYear
Combined Treatment of 6-Gingerol Analog and Tobramycin for Inhibiting Pseudomonas aeruginosa Infections.
    Microbiology spectrum, 2021, 10-31, Volume: 9, Issue:2

    Pseudomonas aeruginosa is a ubiquitous human pathogen that causes severe infections. Although antibiotics, such as tobramycin, are currently used for infection therapy, their antibacterial activity has resulted in the emergence of multiple antibiotic-resistant bacteria. The 6-gingerol analog, a structural derivative of the main component of ginger, is a quorum sensing (QS) inhibitor. However, it has a lower biofilm inhibitory activity than antibiotics and the possibility to cause toxicity in humans. Therefore, novel and more effective approaches for decreasing dosing concentration and increasing biofilm inhibitory activity are required to alleviate P. aeruginosa infections. In this study, a 6-gingerol analog was combined with tobramycin to treat P. aeruginosa infections. The combined treatment of 6-gingerol analog and tobramycin showed strong inhibitory activities on biofilm formation and the production of QS-related virulence factors of P. aeruginosa compared to single treatments. Furthermore, the combined treatment alleviated the infectivity of P. aeruginosa in an insect model using Tenebrio molitor larvae without inducing any cytotoxic effects in human lung epithelial cells. The 6-gingerol analog showed these inhibitory activities at much lower concentrations when used in combination with tobramycin. Adjuvant effects were observed through increased QS-disrupting processes rather than through antibacterial action. In particular, improved RhlR inactivation by this combination is a possible target for therapeutic development in LasR-independent chronic infections. Therefore, the combined treatment of 6-gingerol analog and tobramycin may be considered an effective method for treating P. aeruginosa infections.

    Topics: Anti-Bacterial Agents; Biofilms; Catechols; Cell Line; Cell Proliferation; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Epithelial Cells; Fatty Alcohols; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Respiratory Mucosa; Tobramycin

2021
Exemplifying the next generation of antibiotic susceptibility intensifiers of phytochemicals by LasR-mediated quorum sensing inhibition.
    Scientific reports, 2021, 11-17, Volume: 11, Issue:1

    There persists a constant threat from multidrug resistance being acquired by all human pathogens that challenges the well-being of humans. This phenomenon is predominantly led by Pseudomonas aeruginosa which is already resistant to the current generations of antibiotic by altering its metabolic pathways to survive. Specifically for this microbe the phenomenon of quorum sensing (QS) plays a crucial role in acquiring virulence and pathogenicity. QS is simply the cross talk between the bacterial community driven by signals that bind to receptors, enabling the entire bacterial microcosm to function as a single unit which has led to control P. aeruginosa cumbersome even in presence of antibiotics. Inhibition of QS can, therefore, be of a significant importance to curb such virulent and pathogenic strains of P. aeruginosa. Natural compounds are well known for their antimicrobial properties, of which, information on their mode of action is scarce. There can be many antimicrobial phytochemicals that act by hindering QS-pathways. The rationale of the current study is to identify such natural compounds that can inhibit QS in P. aeruginosa driven by LasR, PhzR, and RhlR dependent pathways. To achieve this rationale, in silico studies were first performed to identify such natural compounds which were then validated by in vitro experiments. Gingerol and Curcumin were identified as QS-antagonists (QSA) which could further suppress the production of biofilm, EPS, pyocyanin, and rhamnolipid along with improving the susceptibility to antibiotics.

    Topics: Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Catechols; Curcumin; Fatty Alcohols; Glycolipids; Microbial Sensitivity Tests; Molecular Dynamics Simulation; Phytochemicals; Pseudomonas aeruginosa; Pseudomonas Infections; Pyocyanine; Quorum Sensing; Signal Transduction; Trans-Activators; Virulence

2021
Discovery and Characterization of Pure RhlR Antagonists against
    Journal of medicinal chemistry, 2020, 08-13, Volume: 63, Issue:15

    Topics: Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Catechols; Drug Discovery; Fatty Alcohols; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing

2020
Structure-Activity Relationships of 6- and 8-Gingerol Analogs as Anti-Biofilm Agents.
    Journal of medicinal chemistry, 2017, 12-14, Volume: 60, Issue:23

    Pseudomonas aeruginosa is a causative agent of chronic infections in immunocompromised patients. Disruption of quorum sensing circuits is an attractive strategy for treating diseases associated with P. aeruginosa infection. In this study, we designed and synthesized a series of gingerol analogs targeting LasR, a master regulator of quorum sensing networks in P. aeruginosa. Structure-activity relationship studies showed that a hydrogen-bonding interaction in the head section, stereochemistry and rotational rigidity in the middle section, and optimal alkyl chain length in the tail section are important factors for the enhancement of LasR-binding affinity and for the inhibition of biofilm formation. The most potent compound 41, an analog of (R)-8-gingerol with restricted rotation, showed stronger LasR-binding affinity and inhibition of biofilm formation than the known LasR antagonist (S)-6-gingerol. This new LasR antagonist can be used as an early lead compound for the development of anti-biofilm agents to treat P. aeruginosa infections.

    Topics: Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Catechols; Fatty Alcohols; Humans; Molecular Docking Simulation; Pseudomonas aeruginosa; Pseudomonas Infections; Quorum Sensing; Trans-Activators

2017